ReviewCirculation reports2026
Vasospastic Angina and Cardiac Arrest.
Review in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vasospastic angina (VSA) is an important and potentially treatable cause of cardiac arrest (CA) and may account for approximately 2-10% of otherwise unexplained cases of out-of-hospital CA. VSA can sometimes be diagnosed by spontaneous coronary spasm during emergency coronary angiography or by transient ST-segment elevation during a spontaneous attack after resuscitation. However, because coronary spasm is transient and may not be evident during the initial evaluation, provocation testing after clinical stabilization may be required to establish the diagnosis in otherwise unexplained cases. Once VSA is diagnosed, vasodilator therapy, particularly calcium-channel blockers, is the mainstay of treatment. Nevertheless, survivors of VSA-related CA may remain at risk of recurrent lethal ventricular arrhythmias despite medical therapy. Evaluation for alternative or overlapping arrhythmogenic disorders, including cardiomyopathies and channelopathies, should therefore be considered even after a diagnosis of VSA, and implantable cardioverter-defibrillator implantation may be considered in selected patients according to the risk of recurrence and response to medical therapy. Further prospective studies, including randomized controlled trials, are needed to determine whether systematic provocation testing followed by targeted therapy reduces recurrent ventricular arrhythmias and CA and improves long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.